Thermo Fisher Scientific has agreed to purchase The Binding Site, a manufacturer of precision diagnostics for melanoma, blood cancer and immune system disorder applications from its current owner, Nordic Capital, in a cash transaction worth £2.25bn ($2.6bn).
The deal, announced 31 October, represents another step in Thermo Fisher’s effort to expand its diagnostics and lab services presence....
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?